47th Annual Carrell Krusen Neuromuscular Symposium (RP2502C)

February 20, 2025 to February 21, 2025

This symposium is a clinical education experience for members of multidisciplinary teams who care for patients with rare, complex neuromuscular diseases including hereditary muscular dystrophies, motor neuron disorders, peripheral autoimmune disorders (such as inflammatory myopathies, neuropathies, myasthenia gravis), and rare genetic disorders of nerve, neuromuscular junction, and muscle. Case presentations will include physical diagnosis and discussion of management and new therapies by participating experts. All discussions involve active participation by attendees. The educational format for this activity includes didactic lectures with in depth Q&A, panel discussions, and PowerPoint Presentations. The content of the program is identified and developed through a Call for Abstracts process. The 2025 keynote speaker will present a formal lecture on congenital myopathies, a group of ultra-rare, single gene disorders that he has studied for 3 decades. He has been a leader in gene discovery for these disorders and a pioneer in developing therapies.

HOW DO I REGISTER?

Click on the "REGISTER" tab, choose the appropriate category, and pay the registration fee

Registration TypeBefore 1/10/25After 1/10/25
Physicians (MD/DO)$200$250
Advanced Practice Providers (PAs/NPs)$150$200
Other Healthcare Professionals (OT/PT/SPL)$150$200
Trainees (Fellows/Residents/Medical Students)$50$75
Nurses$50$75
Research Coordinators$100$125
Exhibit/Industry Representative$275$325

Submit an Abstract

Help shape this year's conference by submitting an abstract! Open to all members of the interdisciplinary team. 

Click HERE to submit an abstract!

The deadline for abstract submission is Friday, November 22, 2024.

Target Audience

This program is specifically designed for Primary Care providers, Neurologists, Nurses, Advanced Practitioners, and Researchers that desire to gain advanced knowledge in diagnosis and management of patients with neuromuscular disease.

Learning Objectives

  1. Discuss genotype/phenotype correlation for the congenital myopathies. 
  2. Review results of clinical trials and plans for upcoming trials. Review management aimed at quality of life.
  3. Discuss recent advances in the genetic diagnosis of neuromuscular disorders, in research and clinical practice and the latest developments in treatment such as gene replacement therapy, cell therapy and forms of RNA therapy.
  4. Identify and apply current pharmacological and non-pharmacological treatments in motor neuron diseases including gene replacement therapy.
  5. Recognize the clinical applications of results of imaging both MRI and ultrasound as well as histopathology in neuromuscular disorders.
Course summary
Available credit: 
  • 9.75 AMA
  • 9.75 Attendance
Course opens: 
09/12/2024
Course expires: 
02/20/2026
Event starts: 
02/20/2025 - 8:00am CST
Event ends: 
02/21/2025 - 3:00pm CST
Cost:
$275.00
Add to calendar: 
Rating: 
0
UT Southwestern Medical Center
T. Boone Pickens Auditorium (NG3.112)
6001 Forest Park Rd.
Dallas 75235
United States

Travel

Hotel Room Block details coming soon!

Committee member(s)

Salman Bhai, MD

has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Taysha Gene Therapies;.
has a financial relationship (Independent contractor) with UCB;.
has a financial relationship (Independent contractor) with Grifols;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Argenx;.
has a financial relationship (Independent contractor) with Epirium Bio;.

Zurisadai Gonzalez Castillo, MD

has no relevant financial relationships to disclose at this time.

Anne Marie Jones, MS, BSN, RN

has no relevant financial relationships to disclose at this time.

Lauren Phillips, MD

has no relevant financial relationships to disclose at this time.

Jaya Trivedi, MD, FAAN, FANA

has no relevant financial relationships to disclose at this time.

Steven Vernino, MD, PhD, FAAN, FANA, FAAS

has a financial relationship (Grant Or Contract) with Grifols;.
has a financial relationship (Grant Or Contract) with Theravance;.
has a financial relationship (Professional Services) with CSL Behring;.
has a financial relationship (Grant Or Contract) with Quest Diagnostics;.
has a financial relationship (Independent contractor) with Antag;.
has a financial relationship (Professional Services) with Amneal;.
has a financial relationship (Fiduciary officer) with American Autonomic Society;.
has a financial relationship (Professional Services) with Argenx;.
has a financial relationship (Professional Services) with Alterity;.
has a financial relationship (Grant Or Contract) with Dysautonomia International;.
has a financial relationship (Grant Or Contract) with Takeda;.
Course Director(s)

Kaitlin Batley, MD

has a financial relationship (Professional Services) with Reata Pharmaceuticals;.
has a financial relationship (Professional Services) with PTC Therapeutics;.
has a financial relationship (Professional Services) with UCB, Inc;.
has a financial relationship (Professional Services) with Biogen, Inc;.
has a financial relationship (Professional Services) with Sarepta Therapeutics;.
has a financial relationship (Professional Services) with Pfizer;.

Susan Iannaccone, MD

has a financial relationship (Grant Or Contract) with Biogen;.
has a financial relationship (Grant Or Contract) with ReveraGen;.
has a financial relationship (Grant Or Contract) with Cure SMA;.
has a financial relationship (Grant Or Contract) with Fibrogen;.
has a financial relationship (Grant Or Contract) with PTC Therapeutics;.
has a financial relationship (Grant Or Contract) with MDA;.
has a financial relationship (Grant Or Contract) with RegenxBio;.
has a financial relationship (Grant Or Contract) with Sarepta;.
has a financial relationship (Grant Or Contract) with NIH;.
has a financial relationship (Grant Or Contract) with Department of Defense;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Grant Or Contract) with Avexis;.
has a financial relationship (Grant Or Contract) with Scholar Rock;.
has a financial relationship (Grant Or Contract) with Parent Project for Muscular Dystrophy;.
has a financial relationship (Grant Or Contract) with Capricor;.

Shaida Khan, D.O.

has a financial relationship (Professional Services) with Argenx;.
has a financial relationship (Professional Services) with UCB Pharma;.
has a financial relationship (Professional Services) with UCB Pharma;.
Peer reviewer(s)

George Bailey

has no relevant financial relationships to disclose at this time.

Erica Knoll, MPAS, PA-C

has no relevant financial relationships to disclose at this time.

Sharon Nations

has no relevant financial relationships to disclose at this time.

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Texas Southwestern Medical Center designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 9.75 AMA
  • 9.75 Attendance

Price

Cost:
$275.00
Please login or create an account to take this course.

To register:

  1. "Login" to your existing account or create an account in EthosCE, online learning management system, by selecting the "create an account" link.
  2. Once logged in, return to this course page, select the designated fee and click the "add to cart" button.
  3. In the following "checkout" pages you will verify and process your payment.
  4. After registration is completed, a confirmation will be sent by email.

A $25 handling fee will be deducted from cancellation refunds. Refund requests must be received by email at CEOffice@utsouthwestern.edu by February 5, 2025.  No refunds will be made thereafter.